Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Stuart Elborn

Showing results (121-130 of 290) with videos related to

Pageof 29
Sort By:
The European Respiratory Journal|March 21, 2015
Future trends in cystic fibrosis demography in 34 European countriesPierre-Régis Burgel, Gil Bellis, Hanne V Olesen, et al.
Critical Care Medicine|October 1, 2009
Extravascular lung water indexed to predicted body weight is a novel predictor of intensive care unit mortality in patients with acute lung injuryThelma R Craig, Martin J Duffy, Murali Shyamsundar, et al.
BMC Pulmonary Medicine|July 2, 2014
Treatment adherence and health outcomes in patients with bronchiectasisAmanda R McCullough, Michael M Tunney, Alexandra L Quittner, et al.
The Ulster Medical Journal|October 23, 2020
TACKLING ANTIMICROBIAL RESISTANCE (AMR) - IN VITRO EFFECT OF SODIUM CHLORIDE ON ANTIBIOTIC SUSCEPTIBILITY IN CLINICAL PSEUDOMONAS AERUGINOSA ISOLATED FROM PATIENTS WITH CYSTIC FIBROSIS (CF)Andrea Gramegna, B Cherie Millar, M Contarini, et al.
Pediatric Pulmonology|May 23, 2012
Cycle ergometer tests in children with cystic fibrosis: reliability and feasibilityLisa Kent, Brenda O'Neill, Gareth Davison, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2013
Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditionsGerard McCaughey, Deirdre F Gilpin, Thamarai Schneiders, et al.
Plos One|September 5, 2014
Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial resultsJudy M Bradley, Paul Koker, Qiqi Deng, et al.
The European Respiratory Journal|September 6, 2015
A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasisAnthony De Soyza, Ian Pavord, J Stuart Elborn, et al.
Journal of Clinical Microbiology|November 8, 2003
Towards "molecular Esperanto" or the Tower of Babel? (the need for harmonization of techniques for genotyping clinical isolates of Pseudomonas aeruginosa isolated from patients with cystic fibrosis)John E Moore, Colin E Goldsmith, J Stuart Elborn, et al.
International Journal of Antimicrobial Agents|August 14, 2018
High prevalence of triazole resistance in clinical Aspergillus fumigatus isolates in a specialist cardiothoracic centreAlireza Abdolrasouli, Andrew Scourfield, Johanna Rhodes, et al.
Pageof 29

Showing results (121-130 of 290) with videos related to

Sort By:
Pageof 29
The European Respiratory Journal|March 21, 2015
Future trends in cystic fibrosis demography in 34 European countriesPierre-Régis Burgel, Gil Bellis, Hanne V Olesen, et al.
Critical Care Medicine|October 1, 2009
Extravascular lung water indexed to predicted body weight is a novel predictor of intensive care unit mortality in patients with acute lung injuryThelma R Craig, Martin J Duffy, Murali Shyamsundar, et al.
BMC Pulmonary Medicine|July 2, 2014
Treatment adherence and health outcomes in patients with bronchiectasisAmanda R McCullough, Michael M Tunney, Alexandra L Quittner, et al.
The Ulster Medical Journal|October 23, 2020
TACKLING ANTIMICROBIAL RESISTANCE (AMR) - IN VITRO EFFECT OF SODIUM CHLORIDE ON ANTIBIOTIC SUSCEPTIBILITY IN CLINICAL PSEUDOMONAS AERUGINOSA ISOLATED FROM PATIENTS WITH CYSTIC FIBROSIS (CF)Andrea Gramegna, B Cherie Millar, M Contarini, et al.
Pediatric Pulmonology|May 23, 2012
Cycle ergometer tests in children with cystic fibrosis: reliability and feasibilityLisa Kent, Brenda O'Neill, Gareth Davison, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2013
Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditionsGerard McCaughey, Deirdre F Gilpin, Thamarai Schneiders, et al.
Plos One|September 5, 2014
Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial resultsJudy M Bradley, Paul Koker, Qiqi Deng, et al.
The European Respiratory Journal|September 6, 2015
A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasisAnthony De Soyza, Ian Pavord, J Stuart Elborn, et al.
Journal of Clinical Microbiology|November 8, 2003
Towards "molecular Esperanto" or the Tower of Babel? (the need for harmonization of techniques for genotyping clinical isolates of Pseudomonas aeruginosa isolated from patients with cystic fibrosis)John E Moore, Colin E Goldsmith, J Stuart Elborn, et al.
International Journal of Antimicrobial Agents|August 14, 2018
High prevalence of triazole resistance in clinical Aspergillus fumigatus isolates in a specialist cardiothoracic centreAlireza Abdolrasouli, Andrew Scourfield, Johanna Rhodes, et al.
Pageof 29